The correct way to buy Capmatinib?

Introduction: On August 10, 2022, the U.S. Food and Drug Administration (FDA) regularly approved capmatinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have mutations that lead to mesenchymal epithelial transition (MET) exon 14 skipping, which is detected by FDA-approved detection methods.

The correct way to purchase generic capmatinib drugs

1. Hospital pharmacies: generic drugs are usually available in some hospitals in countries or regions where generic capmatinib drugs are listed. Patients can purchase them at the hospital pharmacy with a doctor's prescription.

2. Officially authorized online pharmacies: Some officially authorized online pharmacies may provide sales services of generic capmatinib drugs. Patients should pay attention to choosing pharmacies with formal qualifications and good reputation.

3. Medical service institutions: For capmatinib generic drugs that have not yet been launched in the country, you can consider purchasing them through medical service institutions, usually through international drug direct mail. This method requires paying attention to the legality and safety of the drugs, and ensuring that the purchased drugs comply with international drug regulatory requirements.

4. Patient associations or charitable organizations: Some patient associations or charitable organizations may provide drug assistance or funding projects to help patients obtain generic capmatinib drugs at lower prices or for free. Patients can pay attention to the official websites of these organizations or consult relevant personnel to learn whether there are assistance projects for capmatinib.

Patients are advised to be cautious when purchasing generic capmatinib drugs, choose regular channels for purchase, and follow the doctor’s advice and guidance for treatment. At the same time, you should consult relevant laws and regulations before purchasing to avoid illegal purchase and use.

Efficacy of capmatinib in the treatment of lung cancer

In a multicenter, non-randomized, open-label, multi-cohort study, the efficacy of capmatinib was confirmed in 160 patients with metastatic NSCLC with mutations that cause MET exon 14 skipping. Patients received 400 mg of capmatinib orally twice daily until disease progression or unacceptable toxicity. Among the 60 untreated patients, the ORR was 68% and the DOR was 16.6 months. Among 100 treated patients, the ORR was 44% and the DOR was 9.7 months.